Abstract: Process for preparing CHF.sub.2 OCHFCF.sub.3 through the use of novel intermediate compounds CHCl.sub.2 OCH.sub.2 COCl and CHCl.sub.2 OCHClCOCl.

Abstract: Sodium or potassium fluoride has been found to efficiently fluorinate the chloro atom adjacent the ether oxygen in chloro-fluoro organic ethers. The reaction proceeds efficiently without added solvent at an elevated temperature and pressure.

Abstract: Fluoromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether is prepared by reacting bromine trifluoride and methyl 1,1,1,3,3,3-hexachloro-2-propyl ether or chloromethyl 1,1,1,3,3,3-hexachloro-2-propyl ether. The mixed fluorochloro ether intermediates having the formula of ##STR1## (wherein x+y=3, a+b=3, and Z=H Cl, or F) are converted to fluoromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether by reactions with bromine trifluoride.

Abstract: Compounds are disclosed of the formula ##STR1## wherein R.sup.1 is an unsubstituted or substituted herterocyclic ring system; R.sup.2 is an unsubstituted or substituted phenyl; R.sup.3 is a lower alkyl or lower alkoxy, and L is selected from a wide variety of groups.

Abstract: Disclosed are novel enamine quaternary compounds of the formula ##STR1## wherein m=1, 2 or 3 and n=1, 2 or 3 with the proviso that m+n=3, 4 or 5; R.sup.1 and R.sup.2 are independently lower alkyl or hydrogen, and R.sup.3 and R.sup.4 are independently selected from the group consisting of lower alkyl, lower cycloalkyl lower alkyl, lower alkenyl, phenyl lower alkyl, thienyl lower alkyl, furyl lower alkyl, lower alkoxy lower alkyl, halogenated lower alkyl, lower alkyloyloxo or lower alkyloyloxy lower alkyl or wherein NR.sup.3 R.sup.4 together comprise a heterocycle ring; and wherein X.sup.- represents a pharmaceutically acceptable anion. Pharmaceutical compositions containing the same when administered to warm-blooded animals exhibit a muscle relaxant effect characterized by excellent onset and recovery times. Also disclosed are methods of making the enamine quaternary compounds.

Abstract: There is disclosed an injectable anesthetic pharmaceutical composition which does not exhibit muscle rigidity and which includes an anesthetic effective amount of at least one substituted N-(4-piperidinyl)-N-amide and a muscle rigidity inhibiting effective amount of at least one alpha-2 adrenergic agonist as principle ingredients. Also disclosed are methods of inducing and maintaining anesthesia without muscle rigidity by administering said composition to warm blooded animals.

Abstract: Process for preparing CHF.sub.2 OCHFCF.sub.3 through the use of novel intermediate compounds CHCl.sub.2 OCH.sub.2 COCl and CHCl.sub.2 OCHClCOCl.

Abstract: The present invention is directed to an improved stereoselective tandem substitution and reduction of an imine precursor to the cis form of 3-substituted-4-(phenylanilo)piperidine compounds or their substituted derivatives.

Abstract: Compounds are disclosed of the formula ##STR1## Where R.sup.1 is an unsubstituted or substituted heterocyclic ring system; R.sup.2 is an unsubstituted or substituted phenyl; R.sup.3 is a lower alkyl or lower alkoxy, and L is selected from a wide variety of groups.

Abstract: The present invention is directed to an anestesia inducing composition comprising a mixture of oxygen gas and an anesthesia inducing effective amount of a compound 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane having the formula ##STR1## The present invention is also directed to methods of inducing and/or maintaining anesthesia by administering the composition in sufficient amounts to warm blooded animals.